Brief: Regeneus Ltd Says HY Revenue From Ordinary Activities A$20,005 Versus A$7.1 Million
25/02/2022 04:26
Feb 25 (Reuters) - Regeneus Ltd RGS.AX :
* HY REVENUE FROM ORDINARY ACTIVITIES A$20,005 VERSUS A$7.1
MILLION
* HY LOSS ATTRUBUTABLE A$2.7 MILLION VERSUS PROFIT OF A$4.4
MILLION
Further company coverage: RGS.AX
Recent news on Cambium Bio
See all newsAustralia's Cambium Bio hits near three-month high on share placement at premium
Brief: Cambium Bio Appoints Olga Smejkalova As Company Secretary
Australia's Cambium Bio gains after premium share placement
Brief: Cambium Bio Raises A$1 MLN At A$0.48 Per Share
Brief: Cambium Bio Receives A$2.4 Million Investment From Zheng Yang Biomedical Technology